董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stacy Coen | 女 | Independent Director | 55 | 8.43万美元 | 未持股 | 2026-03-13 |
| Pete O Heeron | 男 | Chairperson and Chief Executive Officer | 62 | 106.62万美元 | 39.94 | 2026-03-13 |
| Robert Hoffman | 男 | Director | 60 | 48.37万美元 | 1.05 | 2026-03-13 |
| Victoria Nikla | 女 | Independent Director | 67 | 7.18万美元 | 1.05 | 2026-03-13 |
| Richard Cilento | 男 | Independent Director | 64 | 8.43万美元 | 1.48 | 2026-03-13 |
| Matthew Link | 男 | Independent Director | 51 | 7.68万美元 | 未持股 | 2026-03-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Pete O Heeron | 男 | Chairperson and Chief Executive Officer | 62 | 106.62万美元 | 39.94 | 2026-03-13 |
| Hamid Khoja | 男 | Chief Scientific Officer | 57 | 65.41万美元 | 3.13 | 2026-03-13 |
| Ruben A. Garcia | 男 | General Counsel | 49 | 62.68万美元 | 2.16 | 2026-03-13 |
| Jason D. Davis | 男 | Chief Financial Officer | 53 | 未披露 | 1.05 | 2026-03-13 |
董事简历
中英对照 | 中文 | 英文- Stacy Coen
-
Stacy Coen于2020年6月加入ImmunoGen，自那时起担任我们的高级副总裁兼首席商务官。科恩女士从生物制药公司Editas Medicine加入ImmunoGen，并于2017年至2020年担任该公司业务发展Vice President。在此之前，她于1997年至2017年在制药公司赛诺菲健赞（Sanofi Genzyme）担任了20年的职务，在业务发展领域的责任不断增加。科恩女士拥有弗吉尼亚大学达顿工商管理研究生院工商管理硕士学位、工商管理硕士学位、金融硕士学位和梦百合。Coen女士目前担任美国亨廷顿疾病协会（The Huntington’；s Disease Society of America）的董事会成员。
Stacy Coen has over 25 years of biness and corporate development experience from leading oncology and rare disease companies. She most recently served as Chief Biness Officer for ImmunoGen, Inc., a company that was developing the next generation of antibody drug conjugates to improve outcomes for cancer patients, which was acquired by AbbVie, Inc. Prior to ImmunoGen, Ms. Coen worked at Editas Medicine, Inc., a biotechnology company developing therapies for rare diseases, where she served as Vice President, Biness Development and was responsible for biness development, strategy, transactions and alliance management. Prior to joining Editas, Ms. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now Sanofi), including as Vice President, Head of Rare Disease Biness Development and Licensing, and as Vice President, Global Head of Strategy and Biness Development, Multiple Sclerosis, among others. Ms. Coen currently serves on the Huntington's Disease Society of America's Center Programs & Education Advisory Committee. Ms. Coen received a BS in Finance and Economics from the University of Massachetts and an MBA from the Darden Graduate School of Biness at the University of Virginia. - Stacy Coen于2020年6月加入ImmunoGen，自那时起担任我们的高级副总裁兼首席商务官。科恩女士从生物制药公司Editas Medicine加入ImmunoGen，并于2017年至2020年担任该公司业务发展Vice President。在此之前，她于1997年至2017年在制药公司赛诺菲健赞（Sanofi Genzyme）担任了20年的职务，在业务发展领域的责任不断增加。科恩女士拥有弗吉尼亚大学达顿工商管理研究生院工商管理硕士学位、工商管理硕士学位、金融硕士学位和梦百合。Coen女士目前担任美国亨廷顿疾病协会（The Huntington’；s Disease Society of America）的董事会成员。
- Stacy Coen has over 25 years of biness and corporate development experience from leading oncology and rare disease companies. She most recently served as Chief Biness Officer for ImmunoGen, Inc., a company that was developing the next generation of antibody drug conjugates to improve outcomes for cancer patients, which was acquired by AbbVie, Inc. Prior to ImmunoGen, Ms. Coen worked at Editas Medicine, Inc., a biotechnology company developing therapies for rare diseases, where she served as Vice President, Biness Development and was responsible for biness development, strategy, transactions and alliance management. Prior to joining Editas, Ms. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now Sanofi), including as Vice President, Head of Rare Disease Biness Development and Licensing, and as Vice President, Global Head of Strategy and Biness Development, Multiple Sclerosis, among others. Ms. Coen currently serves on the Huntington's Disease Society of America's Center Programs & Education Advisory Committee. Ms. Coen received a BS in Finance and Economics from the University of Massachetts and an MBA from the Darden Graduate School of Biness at the University of Virginia.
- Pete O Heeron
-
Pete O'Heeron，创立了Fibrobiologics，Inc.，自Fibrobiologics，Inc.于2021年4月成立以来，一直担任Fibrobiologics，Inc.首席执行官，以及Fibrobiologics，Inc.董事会主席和成员。奥希隆先生还是FibroGenesis，Fibrobiologics，Inc.附属公司的创始人，自2006年1月起担任FibroGenesis的首席执行官。奥希隆先生是一位杰出的生物制药发明家，在生物制剂、细胞治疗和医疗设备领域拥有300多项已发布和正在申请的专利。奥希隆先生是该领域一位经验丰富的领导者，在医疗技术和生物技术开发方面拥有超过25年的经验。作为首席执行官，他的目标是使Fibrobiologics公司成为以成纤维细胞为基础的细胞疗法的全球领导者，开发和商业化能够治愈和治疗慢性疾病患者的疗法。奥希隆先生汇集了将独特技术商业化所需的多学科团队和资源。在创立Fibrobiologics，Inc.和FibroGenesis之前，他在2006年创立了一家运营投资集团Advanced Medical Technologies，LLC，该集团发现了具有强大知识产权潜力的医疗领域的早期机会。他还在1998年创立了NeoSurg Technologies，该公司开发了T2000微创接入系统。NeoSurg Technologies于2006年被出售给Cooper Surgical。从1988年至1995年，奥希隆先生还曾在Christus保健公司担任过多个行政级别的职务，并在生物制剂、先进外科仪器和远程医疗领域为医疗保健公司提供战略咨询服务。奥希隆先生在得克萨斯州立大学获得了医疗管理学士学位，在休斯顿大学克利尔湖分校获得了医疗管理硕士学位，在芝加哥大学获得了并购行政管理证书。
Pete O Heeron is a seasoned leader in his field, with over 25 years of experience in medical technology and biotech development. He is also the founder of FibroGenesis, a regenerative medicine company and former parent company, and has served as its Chief Executive Officer since January 2006. Since September 2012, Mr. O'Heeron has also served as Chairman of the Board, Secretary and Treasurer of Liberty Star Uranium & Metals Corp., a company engaged in the acquisition and exploration of mineral properties. Prior to FibroGenesis, in 2006 Mr. O'Heeron founded an operational investment group, Advanced Medical Technologies, LLC, that identified early stage opportunities in the medical field with strong intellectual property potential, and in 1998 he founded NeoSurg Technologies, which developed the T2000 Minimally Invasive Access System and was sold to Cooper Surgical in 2006. Mr. O'Heeron also previoly served in a variety of executive level positions at Christ Health Care Corporation from 1988 until 1995 and has provided strategic advisory services to healthcare companies in the areas of biologics, advanced surgical instrumentation, and telemedicine. Mr. O'Heeron is a preeminent biopharma inventor, with over 300 patents issued and pending in the areas of biologics, cell therapy and medical devices. Mr. O'Heeron received his Bachelor's Degree in Healthcare Administration from Texas State University, his Masters in Healthcare Administration from the University of Hoton Clear Lake, and his Executive Management Certification in Mergers and Acquisition from the University of Chicago. - Pete O'Heeron，创立了Fibrobiologics，Inc.，自Fibrobiologics，Inc.于2021年4月成立以来，一直担任Fibrobiologics，Inc.首席执行官，以及Fibrobiologics，Inc.董事会主席和成员。奥希隆先生还是FibroGenesis，Fibrobiologics，Inc.附属公司的创始人，自2006年1月起担任FibroGenesis的首席执行官。奥希隆先生是一位杰出的生物制药发明家，在生物制剂、细胞治疗和医疗设备领域拥有300多项已发布和正在申请的专利。奥希隆先生是该领域一位经验丰富的领导者，在医疗技术和生物技术开发方面拥有超过25年的经验。作为首席执行官，他的目标是使Fibrobiologics公司成为以成纤维细胞为基础的细胞疗法的全球领导者，开发和商业化能够治愈和治疗慢性疾病患者的疗法。奥希隆先生汇集了将独特技术商业化所需的多学科团队和资源。在创立Fibrobiologics，Inc.和FibroGenesis之前，他在2006年创立了一家运营投资集团Advanced Medical Technologies，LLC，该集团发现了具有强大知识产权潜力的医疗领域的早期机会。他还在1998年创立了NeoSurg Technologies，该公司开发了T2000微创接入系统。NeoSurg Technologies于2006年被出售给Cooper Surgical。从1988年至1995年，奥希隆先生还曾在Christus保健公司担任过多个行政级别的职务，并在生物制剂、先进外科仪器和远程医疗领域为医疗保健公司提供战略咨询服务。奥希隆先生在得克萨斯州立大学获得了医疗管理学士学位，在休斯顿大学克利尔湖分校获得了医疗管理硕士学位，在芝加哥大学获得了并购行政管理证书。
- Pete O Heeron is a seasoned leader in his field, with over 25 years of experience in medical technology and biotech development. He is also the founder of FibroGenesis, a regenerative medicine company and former parent company, and has served as its Chief Executive Officer since January 2006. Since September 2012, Mr. O'Heeron has also served as Chairman of the Board, Secretary and Treasurer of Liberty Star Uranium & Metals Corp., a company engaged in the acquisition and exploration of mineral properties. Prior to FibroGenesis, in 2006 Mr. O'Heeron founded an operational investment group, Advanced Medical Technologies, LLC, that identified early stage opportunities in the medical field with strong intellectual property potential, and in 1998 he founded NeoSurg Technologies, which developed the T2000 Minimally Invasive Access System and was sold to Cooper Surgical in 2006. Mr. O'Heeron also previoly served in a variety of executive level positions at Christ Health Care Corporation from 1988 until 1995 and has provided strategic advisory services to healthcare companies in the areas of biologics, advanced surgical instrumentation, and telemedicine. Mr. O'Heeron is a preeminent biopharma inventor, with over 300 patents issued and pending in the areas of biologics, cell therapy and medical devices. Mr. O'Heeron received his Bachelor's Degree in Healthcare Administration from Texas State University, his Masters in Healthcare Administration from the University of Hoton Clear Lake, and his Executive Management Certification in Mergers and Acquisition from the University of Chicago.
- Robert Hoffman
-
罗伯特·霍夫曼自2021年4月起担任Fibrobiologics，Inc.董事会成员。Hoffman先生目前担任Kintara Therapeutics, Inc.（纳斯达克：KTRA）的总裁、首席执行官和董事会主席，该公司是一家临床阶段的生物制药公司，专注于癌症新疗法的开发和商业化，亚狮康药业有限公司（纳斯达克：ASLN）的董事会成员，该公司是一家专注于肿瘤学的生物技术公司，开发免疫肿瘤药物和靶向疗法组合，Antibe Therapeutics公司董事会主席和成员，Antibe Therapeutics公司是一家总部位于加拿大多伦多的制药公司，在多伦多证券交易所上市。Hoffman先生曾于2017年4月至2020年10月担任处于商业化阶段的生物技术公司Heron Therapeutics, Inc.（纳斯达克：HRTX）的高级副总裁兼首席财务官，并于2015年7月至2016年9月担任专业制药公司AnaptysBio（纳斯达克：ANAB）的首席财务官。从2012年6月至2015年7月，霍夫曼先生担任生物制药公司Arena Pharmaceuticals, Inc.的高级副总裁、财务和首席财务官，在2022年3月被辉瑞公司收购之前。从2011年8月至2012年6月，以及之前的2005年12月至2011年3月，霍夫曼先生担任Arena的副总裁、财务和首席财务官，并在1997年至2005年12月期间担任多个不同的职务，职责日益增加。霍夫曼先生曾于2021年9月至2022年5月担任生物制药公司Saniona AB的董事会成员，并于2015年3月至2021年8月担任癌症研究公司Kura Oncology, Inc.（纳斯达克：KURA）的董事会成员。他还曾担任分子诊断公司CombiMatrix Corporation、生物制药公司MabVax Therapeutics Holdings，Inc.和临床阶段生物技术公司Aravive, Inc.（纳斯达克：ARAV）的董事会成员。Hoffman先生是生物科学财务干事协会指导委员会的成员。霍夫曼先生曾担任国际财务主管圣地亚哥分会的董事和总裁，并于2010年至2020年担任财务会计准则委员会（FASB）的顾问，就新出现的问题和新的财务指导意见向美国会计准则制定组织提供咨询。霍夫曼先生拥有圣博纳文大学的学士学位。
Robert Hoffman has served as Chief Financial Officer of CytoDyn Inc., a clinical stage biotechnology company. Mr. Hoffman previoly served as President, CEO and Chairperson of the board of directors of Kintara Therapeutics, Inc. (Nasdaq: KTRA), a clinical stage, biopharmaceutical company foced on the development and commercialization of new cancer therapies, from November 2021 to October 2024, when it merged with TuHURA Biosciences, Inc. (Nasdaq: HURA), or TuHURA. Prior to that, Mr. Hoffman served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc., (Nasdaq: HRTX), a commercial stage biotechnology company, from April 2017 to October 2020, and as Chief Financial Officer of AnaptysBio, Inc. (Nasdaq: ANAB), a specialty pharmaceutical company, from July 2015 to September 2016. From June 2012 to July 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc., or Arena, a biopharmaceutical company, prior to its acquisition by Pfizer Inc. in March 2022. From Augt 2011 to June 2012 and previoly from December 2005 to March 2011, Mr. Hoffman served as Arena's Vice President, Finance and Chief Financial Officer and in a number of vario roles of increasing responsibility from 1997 to December 2005. He is a member of the board of directors of TuHURA, a Phase 3 registration stage immuno oncology company, and Esperion Therapeutics, Inc. (Nasdaq: ESPR), a commercial stage biopharmaceutical company. Mr. Hoffman formerly served as a member of the board of directors of ASLAN Pharmaceuticals Limited (Nasdaq: ASLN), a dermatology foced biotechnology company, from October 2018 to October 2024, Kintara Therapeutics, Inc., from April 2018 to October 2024, Saniona AB, a biopharmaceutical company, from September 2021 to May 2022, and Kura Oncology, Inc. (Nasdaq: KURA), a cancer research company, from March 2015 to Augt 2021. He also previoly served as a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, MabVax Therapeutics Holdings, Inc., a biopharmaceutical company, and Aravive, Inc. (Nasdaq: ARAV), a clinical stage biotechnology company. Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standard Board, or FASB, from 2010 to 2020, advising the U.S. accounting rulemaking organization on emerging issues and new financial guidance. Mr. Hoffman holds a B.B.A. from St. Bonaventure University. - 罗伯特·霍夫曼自2021年4月起担任Fibrobiologics，Inc.董事会成员。Hoffman先生目前担任Kintara Therapeutics, Inc.（纳斯达克：KTRA）的总裁、首席执行官和董事会主席，该公司是一家临床阶段的生物制药公司，专注于癌症新疗法的开发和商业化，亚狮康药业有限公司（纳斯达克：ASLN）的董事会成员，该公司是一家专注于肿瘤学的生物技术公司，开发免疫肿瘤药物和靶向疗法组合，Antibe Therapeutics公司董事会主席和成员，Antibe Therapeutics公司是一家总部位于加拿大多伦多的制药公司，在多伦多证券交易所上市。Hoffman先生曾于2017年4月至2020年10月担任处于商业化阶段的生物技术公司Heron Therapeutics, Inc.（纳斯达克：HRTX）的高级副总裁兼首席财务官，并于2015年7月至2016年9月担任专业制药公司AnaptysBio（纳斯达克：ANAB）的首席财务官。从2012年6月至2015年7月，霍夫曼先生担任生物制药公司Arena Pharmaceuticals, Inc.的高级副总裁、财务和首席财务官，在2022年3月被辉瑞公司收购之前。从2011年8月至2012年6月，以及之前的2005年12月至2011年3月，霍夫曼先生担任Arena的副总裁、财务和首席财务官，并在1997年至2005年12月期间担任多个不同的职务，职责日益增加。霍夫曼先生曾于2021年9月至2022年5月担任生物制药公司Saniona AB的董事会成员，并于2015年3月至2021年8月担任癌症研究公司Kura Oncology, Inc.（纳斯达克：KURA）的董事会成员。他还曾担任分子诊断公司CombiMatrix Corporation、生物制药公司MabVax Therapeutics Holdings，Inc.和临床阶段生物技术公司Aravive, Inc.（纳斯达克：ARAV）的董事会成员。Hoffman先生是生物科学财务干事协会指导委员会的成员。霍夫曼先生曾担任国际财务主管圣地亚哥分会的董事和总裁，并于2010年至2020年担任财务会计准则委员会（FASB）的顾问，就新出现的问题和新的财务指导意见向美国会计准则制定组织提供咨询。霍夫曼先生拥有圣博纳文大学的学士学位。
- Robert Hoffman has served as Chief Financial Officer of CytoDyn Inc., a clinical stage biotechnology company. Mr. Hoffman previoly served as President, CEO and Chairperson of the board of directors of Kintara Therapeutics, Inc. (Nasdaq: KTRA), a clinical stage, biopharmaceutical company foced on the development and commercialization of new cancer therapies, from November 2021 to October 2024, when it merged with TuHURA Biosciences, Inc. (Nasdaq: HURA), or TuHURA. Prior to that, Mr. Hoffman served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc., (Nasdaq: HRTX), a commercial stage biotechnology company, from April 2017 to October 2020, and as Chief Financial Officer of AnaptysBio, Inc. (Nasdaq: ANAB), a specialty pharmaceutical company, from July 2015 to September 2016. From June 2012 to July 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc., or Arena, a biopharmaceutical company, prior to its acquisition by Pfizer Inc. in March 2022. From Augt 2011 to June 2012 and previoly from December 2005 to March 2011, Mr. Hoffman served as Arena's Vice President, Finance and Chief Financial Officer and in a number of vario roles of increasing responsibility from 1997 to December 2005. He is a member of the board of directors of TuHURA, a Phase 3 registration stage immuno oncology company, and Esperion Therapeutics, Inc. (Nasdaq: ESPR), a commercial stage biopharmaceutical company. Mr. Hoffman formerly served as a member of the board of directors of ASLAN Pharmaceuticals Limited (Nasdaq: ASLN), a dermatology foced biotechnology company, from October 2018 to October 2024, Kintara Therapeutics, Inc., from April 2018 to October 2024, Saniona AB, a biopharmaceutical company, from September 2021 to May 2022, and Kura Oncology, Inc. (Nasdaq: KURA), a cancer research company, from March 2015 to Augt 2021. He also previoly served as a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company, MabVax Therapeutics Holdings, Inc., a biopharmaceutical company, and Aravive, Inc. (Nasdaq: ARAV), a clinical stage biotechnology company. Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standard Board, or FASB, from 2010 to 2020, advising the U.S. accounting rulemaking organization on emerging issues and new financial guidance. Mr. Hoffman holds a B.B.A. from St. Bonaventure University.
- Victoria Nikla
-
Victoria Nikla自2021年4月起担任Fibrobiologics，Inc.董事会成员。Niklas博士在转化研究、临床护理和学术健康中心的教学方面拥有20多年的杰出职业生涯，目前是Oak Hill Bio的首席医疗官，这是一家临床阶段的新生儿科和罕见病治疗公司，她从2022年开始担任该职位。在加入Oak Hill Bio之前，Niklas博士曾在全球医疗事务部门任职，并在武田制药担任OHB-607罕见病和血液学项目的全球项目负责人。在加入武田之前，她是Prolacta Bioscience的首席医学和科学官，这是一家基于人类供体乳的新生儿营养产品开发公司。Niklas博士拥有20多年的新生儿科学术经验，在肠道、肺部和黏膜免疫系统的发育性和后天炎症性疾病方面具有专长，这些疾病在整个生命周期中都与疾病相关。她曾担任Nemours儿童医院新生儿医学部主任，加州大学洛杉矶分校Olive View医疗中心新生儿科主任，加州大学洛杉矶分校David Geffen医学院临床儿科客座教授。Niklas博士拥有围产期和新生儿医学委员会认证，并持有加州医疗执照。除了是众多科学和临床出版物的合著者外，她还帮助领导了专利产品的开发，并担任多家生物技术和功能性食品早期公司的董事会成员。Niklas博士在哈佛大学医学院获得医学博士学位，在哈佛大学获得生物化学和分子生物学硕士学位，在Goucher学院获得生物科学学士学位。
Victoria Nikla has a distinguished career spanning more than two decades in translational research, clinical care, and teaching at academic health centers, and is currently the Chief Medical Officer of Oak Hill Bio, a clinical stage neonatology and rare disease therapeutics company, a position she has held since 2022. Prior to joining Oak Hill Bio, Dr. Niklas served in Global Medical Affairs and as Global Program Leader of the OHB 607 program in Rare Disease and Hematology at Takeda Pharmaceuticals. Before Takeda, she was Chief Medical and Scientific Officer at Prolacta Bioscience, a neonatal nutritional product development company based on human donor milk. Dr. Niklas has nearly 30 years of experience as an academic neonatologist with expertise in developmental and acquired inflammatory disorders of the gut, the lung, and the mucosal immune system with relevance to diseases across the lifespan. She has nearly 10 years of experience in industry holding executive positions as ll as program leadership roles. She has also held leadership positions in academic medicine service as Chief, Division of Newborn Medicine at Nems Children's Hospital, Chief of Neonatology at UCLA Olive View Medical Center, and Visiting Professor of Clinical Pediatrics at the David Geffen School of Medicine at UCLA. Dr. Niklas is board certified in Perinatal and Neonatal Medicine and holds a California medical license. In addition to being a co author on numero scientific and clinical publications, she has helped lead the development of patented products and has served as a board member for multiple biotech and early stage companies in functional foods. Dr. Niklas received her MD from Harvard Medical School, her MA in Biochemistry and Molecular Biology from Harvard University, and her bachelor's in Biological Sciences from Goucher College. - Victoria Nikla自2021年4月起担任Fibrobiologics，Inc.董事会成员。Niklas博士在转化研究、临床护理和学术健康中心的教学方面拥有20多年的杰出职业生涯，目前是Oak Hill Bio的首席医疗官，这是一家临床阶段的新生儿科和罕见病治疗公司，她从2022年开始担任该职位。在加入Oak Hill Bio之前，Niklas博士曾在全球医疗事务部门任职，并在武田制药担任OHB-607罕见病和血液学项目的全球项目负责人。在加入武田之前，她是Prolacta Bioscience的首席医学和科学官，这是一家基于人类供体乳的新生儿营养产品开发公司。Niklas博士拥有20多年的新生儿科学术经验，在肠道、肺部和黏膜免疫系统的发育性和后天炎症性疾病方面具有专长，这些疾病在整个生命周期中都与疾病相关。她曾担任Nemours儿童医院新生儿医学部主任，加州大学洛杉矶分校Olive View医疗中心新生儿科主任，加州大学洛杉矶分校David Geffen医学院临床儿科客座教授。Niklas博士拥有围产期和新生儿医学委员会认证，并持有加州医疗执照。除了是众多科学和临床出版物的合著者外，她还帮助领导了专利产品的开发，并担任多家生物技术和功能性食品早期公司的董事会成员。Niklas博士在哈佛大学医学院获得医学博士学位，在哈佛大学获得生物化学和分子生物学硕士学位，在Goucher学院获得生物科学学士学位。
- Victoria Nikla has a distinguished career spanning more than two decades in translational research, clinical care, and teaching at academic health centers, and is currently the Chief Medical Officer of Oak Hill Bio, a clinical stage neonatology and rare disease therapeutics company, a position she has held since 2022. Prior to joining Oak Hill Bio, Dr. Niklas served in Global Medical Affairs and as Global Program Leader of the OHB 607 program in Rare Disease and Hematology at Takeda Pharmaceuticals. Before Takeda, she was Chief Medical and Scientific Officer at Prolacta Bioscience, a neonatal nutritional product development company based on human donor milk. Dr. Niklas has nearly 30 years of experience as an academic neonatologist with expertise in developmental and acquired inflammatory disorders of the gut, the lung, and the mucosal immune system with relevance to diseases across the lifespan. She has nearly 10 years of experience in industry holding executive positions as ll as program leadership roles. She has also held leadership positions in academic medicine service as Chief, Division of Newborn Medicine at Nems Children's Hospital, Chief of Neonatology at UCLA Olive View Medical Center, and Visiting Professor of Clinical Pediatrics at the David Geffen School of Medicine at UCLA. Dr. Niklas is board certified in Perinatal and Neonatal Medicine and holds a California medical license. In addition to being a co author on numero scientific and clinical publications, she has helped lead the development of patented products and has served as a board member for multiple biotech and early stage companies in functional foods. Dr. Niklas received her MD from Harvard Medical School, her MA in Biochemistry and Molecular Biology from Harvard University, and her bachelor's in Biological Sciences from Goucher College.
- Richard Cilento
-
Richard Cilento自2021年4月起担任Fibrobiologics，Inc.董事会成员。Cilento先生是生命科学研发公司GlycosBio Inc.的创始人、董事会主席和首席执行官。Cilento先生是信息技术、供应链管理和税务自动化技术提供商FuelQuest公司的创始人、总裁兼首席执行官，该公司于2007年5月被Saracen Energy Advisors LP收购。Cilento先生曾在多家技术公司担任高级管理职位，包括施乐公司，他曾在该公司担任施乐 Connect战略服务副总裁。在此之前，他是XLConnect Solutions的企业服务副总裁，担任高级系统的首席技术专家，并支持该组织的首次公开发行和最终与施乐的合并。奇伦托是一名航空和天文工程师，他的职业生涯始于美国国家航空航天局（NASA），在那里，他和他的团队为美国国防部的“星球大战”计划和一系列政府资助的技术和生命科学实验制定了航天飞机飞行计划。Cilento先生是设计和规划建造国际空间站的空间站组装序列的首席工程师。Cilento先生拥有伊利诺伊大学航空和天文工程学士学位和休斯顿大学MBA学位。
Richard Cilento is the founder, Chairperson of the board of directors and Chief Executive Officer of GlycosBio Inc., a life sciences research and development company. Mr. Cilento was the founder, President and Chief Executive Officer of FuelQuest, Inc., a provider of information technology, supply chain management and tax automation technologies, which was acquired by Saracen Energy Advisors LP in May 2007. Mr. Cilento has held senior management positions with several technology firms, including Xerox Corporation, where he served as Vice President of Strategic Services of Xerox Connect. Prior to that, he was the Vice President of Corporate Services for XLConnect Solutions, where he served as the lead technologist for advanced systems and supported the organization through its initial public offering and its eventual merger with Xerox. An aeronautical and astronomical engineer, Mr. Cilento began his career at the U.S. National Aeronautics and Space Administration (NASA), where he and his team built space shuttle flight plans for the U.S. Department of Defense Star Wars program and a diverse set of government funded technology and life science experimentation. Mr. Cilento was a lead engineer who designed and planned the space station assembly sequences for the construction of the International Space Station. Mr. Cilento holds a BS degree in Aeronautical and Astronomical Engineering from the University of Illinois and an MBA at the University of Hoton, Clear Lake. - Richard Cilento自2021年4月起担任Fibrobiologics，Inc.董事会成员。Cilento先生是生命科学研发公司GlycosBio Inc.的创始人、董事会主席和首席执行官。Cilento先生是信息技术、供应链管理和税务自动化技术提供商FuelQuest公司的创始人、总裁兼首席执行官，该公司于2007年5月被Saracen Energy Advisors LP收购。Cilento先生曾在多家技术公司担任高级管理职位，包括施乐公司，他曾在该公司担任施乐 Connect战略服务副总裁。在此之前，他是XLConnect Solutions的企业服务副总裁，担任高级系统的首席技术专家，并支持该组织的首次公开发行和最终与施乐的合并。奇伦托是一名航空和天文工程师，他的职业生涯始于美国国家航空航天局（NASA），在那里，他和他的团队为美国国防部的“星球大战”计划和一系列政府资助的技术和生命科学实验制定了航天飞机飞行计划。Cilento先生是设计和规划建造国际空间站的空间站组装序列的首席工程师。Cilento先生拥有伊利诺伊大学航空和天文工程学士学位和休斯顿大学MBA学位。
- Richard Cilento is the founder, Chairperson of the board of directors and Chief Executive Officer of GlycosBio Inc., a life sciences research and development company. Mr. Cilento was the founder, President and Chief Executive Officer of FuelQuest, Inc., a provider of information technology, supply chain management and tax automation technologies, which was acquired by Saracen Energy Advisors LP in May 2007. Mr. Cilento has held senior management positions with several technology firms, including Xerox Corporation, where he served as Vice President of Strategic Services of Xerox Connect. Prior to that, he was the Vice President of Corporate Services for XLConnect Solutions, where he served as the lead technologist for advanced systems and supported the organization through its initial public offering and its eventual merger with Xerox. An aeronautical and astronomical engineer, Mr. Cilento began his career at the U.S. National Aeronautics and Space Administration (NASA), where he and his team built space shuttle flight plans for the U.S. Department of Defense Star Wars program and a diverse set of government funded technology and life science experimentation. Mr. Cilento was a lead engineer who designed and planned the space station assembly sequences for the construction of the International Space Station. Mr. Cilento holds a BS degree in Aeronautical and Astronomical Engineering from the University of Illinois and an MBA at the University of Hoton, Clear Lake.
- Matthew Link
-
Matthew Link，自2021年4月起担任Fibrobiologics，Inc.董事会成员。Link先生在医疗保健和医疗技术行业拥有20多年的经验，目前担任Sight Sciences（SGHT）的首席商务官。2021年至2023年，他在咨询服务提供商Orion Healthcare Advisors，LLC担任管理合伙人。从2006年到2021年，林克曾在NuVasive公司担任区域和行政领导职务，该公司是外科植入物和脊柱外科和骨科支持技术的全球领导者。作为NuVasive，Inc.的总裁，他的职责包括监督脊柱、神经生理学和骨科的全球业务部门。在加入NuVasive公司之前，林克曾在Depuy Orthopedics和Depuy Spine担任商业领导职务。他目前还担任盖伦机器人公司的董事会主席，以及Springbok Analytics和DinamicOR以及弗吉尼亚大学库尔特转化研究基金会的董事会成员。林克先生在弗吉尼亚大学获得了体育和运动医学学士学位。
Matthew Link has more than 20 years of experience in the healthcare and medical technology indtries and currently serves as Managing Director of HealthpointCapital, a private equity firm in the mculoskeletal healthcare space. Mr. Link previoly served as Chief Commercial Officer for Sight Sciences, an eyecare technology company, beten September 2023 and Augt 2025. From 2021 to 2023 he served as managing partner at Orion Healthcare Advisors, LLC, a consulting services provider. From 2006 to 2021 Mr. Link served in regional and executive leadership positions at NuVasive Inc., a global leader in surgical implants and enabling technology for spine surgery and orthopedics. As President of NuVasive, Inc., his responsibilities included oversight of global biness units in spine, neurophysiology, and orthopedics. Prior to NuVasive, Inc., Mr. Link held commercial leadership roles at Depuy Orthopedics and Depuy Spine. He also currently serves as chairman of the board of directors at Galen Robotics and as a member of the board of directors of Springbok Analytics and DinamicOR, and the Coulter Translational Research Endowment at the University of Virginia. Mr. Link received a BSEd in Physical Education and Sports Medicine from the University of Virginia. - Matthew Link，自2021年4月起担任Fibrobiologics，Inc.董事会成员。Link先生在医疗保健和医疗技术行业拥有20多年的经验，目前担任Sight Sciences（SGHT）的首席商务官。2021年至2023年，他在咨询服务提供商Orion Healthcare Advisors，LLC担任管理合伙人。从2006年到2021年，林克曾在NuVasive公司担任区域和行政领导职务，该公司是外科植入物和脊柱外科和骨科支持技术的全球领导者。作为NuVasive，Inc.的总裁，他的职责包括监督脊柱、神经生理学和骨科的全球业务部门。在加入NuVasive公司之前，林克曾在Depuy Orthopedics和Depuy Spine担任商业领导职务。他目前还担任盖伦机器人公司的董事会主席，以及Springbok Analytics和DinamicOR以及弗吉尼亚大学库尔特转化研究基金会的董事会成员。林克先生在弗吉尼亚大学获得了体育和运动医学学士学位。
- Matthew Link has more than 20 years of experience in the healthcare and medical technology indtries and currently serves as Managing Director of HealthpointCapital, a private equity firm in the mculoskeletal healthcare space. Mr. Link previoly served as Chief Commercial Officer for Sight Sciences, an eyecare technology company, beten September 2023 and Augt 2025. From 2021 to 2023 he served as managing partner at Orion Healthcare Advisors, LLC, a consulting services provider. From 2006 to 2021 Mr. Link served in regional and executive leadership positions at NuVasive Inc., a global leader in surgical implants and enabling technology for spine surgery and orthopedics. As President of NuVasive, Inc., his responsibilities included oversight of global biness units in spine, neurophysiology, and orthopedics. Prior to NuVasive, Inc., Mr. Link held commercial leadership roles at Depuy Orthopedics and Depuy Spine. He also currently serves as chairman of the board of directors at Galen Robotics and as a member of the board of directors of Springbok Analytics and DinamicOR, and the Coulter Translational Research Endowment at the University of Virginia. Mr. Link received a BSEd in Physical Education and Sports Medicine from the University of Virginia.
高管简历
中英对照 | 中文 | 英文- Pete O Heeron
Pete O'Heeron，创立了Fibrobiologics，Inc.，自Fibrobiologics，Inc.于2021年4月成立以来，一直担任Fibrobiologics，Inc.首席执行官，以及Fibrobiologics，Inc.董事会主席和成员。奥希隆先生还是FibroGenesis，Fibrobiologics，Inc.附属公司的创始人，自2006年1月起担任FibroGenesis的首席执行官。奥希隆先生是一位杰出的生物制药发明家，在生物制剂、细胞治疗和医疗设备领域拥有300多项已发布和正在申请的专利。奥希隆先生是该领域一位经验丰富的领导者，在医疗技术和生物技术开发方面拥有超过25年的经验。作为首席执行官，他的目标是使Fibrobiologics公司成为以成纤维细胞为基础的细胞疗法的全球领导者，开发和商业化能够治愈和治疗慢性疾病患者的疗法。奥希隆先生汇集了将独特技术商业化所需的多学科团队和资源。在创立Fibrobiologics，Inc.和FibroGenesis之前，他在2006年创立了一家运营投资集团Advanced Medical Technologies，LLC，该集团发现了具有强大知识产权潜力的医疗领域的早期机会。他还在1998年创立了NeoSurg Technologies，该公司开发了T2000微创接入系统。NeoSurg Technologies于2006年被出售给Cooper Surgical。从1988年至1995年，奥希隆先生还曾在Christus保健公司担任过多个行政级别的职务，并在生物制剂、先进外科仪器和远程医疗领域为医疗保健公司提供战略咨询服务。奥希隆先生在得克萨斯州立大学获得了医疗管理学士学位，在休斯顿大学克利尔湖分校获得了医疗管理硕士学位，在芝加哥大学获得了并购行政管理证书。
Pete O Heeron is a seasoned leader in his field, with over 25 years of experience in medical technology and biotech development. He is also the founder of FibroGenesis, a regenerative medicine company and former parent company, and has served as its Chief Executive Officer since January 2006. Since September 2012, Mr. O'Heeron has also served as Chairman of the Board, Secretary and Treasurer of Liberty Star Uranium & Metals Corp., a company engaged in the acquisition and exploration of mineral properties. Prior to FibroGenesis, in 2006 Mr. O'Heeron founded an operational investment group, Advanced Medical Technologies, LLC, that identified early stage opportunities in the medical field with strong intellectual property potential, and in 1998 he founded NeoSurg Technologies, which developed the T2000 Minimally Invasive Access System and was sold to Cooper Surgical in 2006. Mr. O'Heeron also previoly served in a variety of executive level positions at Christ Health Care Corporation from 1988 until 1995 and has provided strategic advisory services to healthcare companies in the areas of biologics, advanced surgical instrumentation, and telemedicine. Mr. O'Heeron is a preeminent biopharma inventor, with over 300 patents issued and pending in the areas of biologics, cell therapy and medical devices. Mr. O'Heeron received his Bachelor's Degree in Healthcare Administration from Texas State University, his Masters in Healthcare Administration from the University of Hoton Clear Lake, and his Executive Management Certification in Mergers and Acquisition from the University of Chicago.- Pete O'Heeron，创立了Fibrobiologics，Inc.，自Fibrobiologics，Inc.于2021年4月成立以来，一直担任Fibrobiologics，Inc.首席执行官，以及Fibrobiologics，Inc.董事会主席和成员。奥希隆先生还是FibroGenesis，Fibrobiologics，Inc.附属公司的创始人，自2006年1月起担任FibroGenesis的首席执行官。奥希隆先生是一位杰出的生物制药发明家，在生物制剂、细胞治疗和医疗设备领域拥有300多项已发布和正在申请的专利。奥希隆先生是该领域一位经验丰富的领导者，在医疗技术和生物技术开发方面拥有超过25年的经验。作为首席执行官，他的目标是使Fibrobiologics公司成为以成纤维细胞为基础的细胞疗法的全球领导者，开发和商业化能够治愈和治疗慢性疾病患者的疗法。奥希隆先生汇集了将独特技术商业化所需的多学科团队和资源。在创立Fibrobiologics，Inc.和FibroGenesis之前，他在2006年创立了一家运营投资集团Advanced Medical Technologies，LLC，该集团发现了具有强大知识产权潜力的医疗领域的早期机会。他还在1998年创立了NeoSurg Technologies，该公司开发了T2000微创接入系统。NeoSurg Technologies于2006年被出售给Cooper Surgical。从1988年至1995年，奥希隆先生还曾在Christus保健公司担任过多个行政级别的职务，并在生物制剂、先进外科仪器和远程医疗领域为医疗保健公司提供战略咨询服务。奥希隆先生在得克萨斯州立大学获得了医疗管理学士学位，在休斯顿大学克利尔湖分校获得了医疗管理硕士学位，在芝加哥大学获得了并购行政管理证书。
- Pete O Heeron is a seasoned leader in his field, with over 25 years of experience in medical technology and biotech development. He is also the founder of FibroGenesis, a regenerative medicine company and former parent company, and has served as its Chief Executive Officer since January 2006. Since September 2012, Mr. O'Heeron has also served as Chairman of the Board, Secretary and Treasurer of Liberty Star Uranium & Metals Corp., a company engaged in the acquisition and exploration of mineral properties. Prior to FibroGenesis, in 2006 Mr. O'Heeron founded an operational investment group, Advanced Medical Technologies, LLC, that identified early stage opportunities in the medical field with strong intellectual property potential, and in 1998 he founded NeoSurg Technologies, which developed the T2000 Minimally Invasive Access System and was sold to Cooper Surgical in 2006. Mr. O'Heeron also previoly served in a variety of executive level positions at Christ Health Care Corporation from 1988 until 1995 and has provided strategic advisory services to healthcare companies in the areas of biologics, advanced surgical instrumentation, and telemedicine. Mr. O'Heeron is a preeminent biopharma inventor, with over 300 patents issued and pending in the areas of biologics, cell therapy and medical devices. Mr. O'Heeron received his Bachelor's Degree in Healthcare Administration from Texas State University, his Masters in Healthcare Administration from the University of Hoton Clear Lake, and his Executive Management Certification in Mergers and Acquisition from the University of Chicago.
- Hamid Khoja
Hamid Khoja自2021年8月起担任Fibrobiologics，Inc.首席科学官。Khoja博士拥有超过25年的经验，担任科学团队的领导者，开发基于细胞的基因组、蛋白质组学、表观遗传学分析，以及Fibrobiologics，Inc.在药物发现和开发以及临床诊断方面的工具、协议和技术。在加入Fibrobiologics，Inc.之前，Khoja博士最近于2009年3月至2021年8月担任首席科学家Covaris，LLC，这是一家私营科学工具公司，专注于基因组学、表观遗传学和蛋白质组学，在那里他向首席执行官提供长期战略应用建议，管理产品和应用开发的外部合作，评估新技术的收购和代工机会，并在许多科学会议上展示海报和演讲。Khoja博士领导了这项工作，成功地将Covaris技术纳入依诺米那下一代测序技术协议，导致超过15,000次引用。Khoja博士还开发了Covaris染色质免疫沉淀方法，在同行评议的出版物中被引用了3000多次，并在Fibrobiologics，Inc.和临床Fibrobiologics，Inc.的表观遗传学分析工作流程方面领导了Covaris技术的努力。Khoja博士还领导了与美国国家癌症研究所的合作，成功开发了微生物组DNA提取Fibrobiologics，Inc.和声学，并完成了FDA EUA SARA-CoC-2桥研究设计，以批准新的样本采集和病毒核糖核酸（RNA）提取Fibrobiologics，Inc.和Covaris技术。Khoja博士还为Fibrobiologics，Inc.开发了一个制造合成无细胞DNA的专利工作流程，作为基于测序的液体活检临床肿瘤学分析的参考标准。在加入Covaris之前，霍亚博士于2022年3月至2009年3月在Genomic Solutions担任高级应用科学家，该公司是一家初创科学工具公司，后来被Harvard Apparatus收购。在那里，他领导了制药行业的高通量蛋白质结晶平台Fibrobiologics，Inc.的开发，用于药物开发，管理科学应用团队，在科学会议上展示公司资源，评估新技术，以获取收购和代工机会。从2000年1月到2003年3月，在Sequenom, Inc.的启动阶段，Khoja博士建立了高度多重聚合酶链反应的方法，即PCR，Fibrobiologics，Inc.开发了Sequenom的massEXTEND技术，用于单核苷酸多态性和遗传病的MALDI-TOF MS分析。Khoja博士领导了针对血色素沉着病、囊性纤维化和十种主要为犹太人的遗传病的基于MS的诊断检测，Fibrobiologics，Inc.和Sequenom的massEXTEND技术随后被转让给一家大型临床诊断公司。Khoja博士还曾于1998年11月至1999年9月在礼来公司工作，并于1995年10月至1998年10月在Chiron公司工作。在礼来工作期间，Khoja博士建立了一个高通量PCR和测序策略Fibrobiologics，Inc.，在1999年提供了各种测序策略和生物信息学工具，用于获得高覆盖基因组测序，最终完成了第一个完整的肺炎链球菌基因组序列。在后来被诺华收购的Chiron公司，Khoja博士帮助设计、开发和优化了FGFR、VEGF、PDGF和EPO受体的HTP结合分析，鉴定了新型g蛋白偶联的七种跨膜受体，鉴定了参与TNF信号通路的新型蛋白质，并开发了基于分支DNA的HTP筛选，用于配体诱导的癌基因定量。Khoja在南加州大学获得分子生物学学士学位，在波士顿大学获得分子生物学博士学位。
Hamid Khoja has more than 25 years of experience leading scientific teams, developing cell based genomic, proteomic, and epigenetics assays, and tools, protocols, and technologies for e in drug discovery, and in development and clinical diagnostics. From March 2009 to Augt 2021, he served as the Principal Scientist at Covaris, LLC, or Corvaris, a privately held scientific tools company with emphasis in genomics, epigenetics, and proteomics. Prior to Covaris, from March 2002 to March 2009, Dr. Khoja was a Senior Applications Scientist at Genomic Solutions, a startup scientific tools company. Dr. Khoja also previoly worked at Eli Lilly and Company from November 1998 to September 1999 and Chiron Corporation from October 1995 to October 1998. Dr. Khoja received his Bachelor of Science in Molecular Biology from the University of Southern California and his Ph.D. in Molecular Biology from Boston University.- Hamid Khoja自2021年8月起担任Fibrobiologics，Inc.首席科学官。Khoja博士拥有超过25年的经验，担任科学团队的领导者，开发基于细胞的基因组、蛋白质组学、表观遗传学分析，以及Fibrobiologics，Inc.在药物发现和开发以及临床诊断方面的工具、协议和技术。在加入Fibrobiologics，Inc.之前，Khoja博士最近于2009年3月至2021年8月担任首席科学家Covaris，LLC，这是一家私营科学工具公司，专注于基因组学、表观遗传学和蛋白质组学，在那里他向首席执行官提供长期战略应用建议，管理产品和应用开发的外部合作，评估新技术的收购和代工机会，并在许多科学会议上展示海报和演讲。Khoja博士领导了这项工作，成功地将Covaris技术纳入依诺米那下一代测序技术协议，导致超过15,000次引用。Khoja博士还开发了Covaris染色质免疫沉淀方法，在同行评议的出版物中被引用了3000多次，并在Fibrobiologics，Inc.和临床Fibrobiologics，Inc.的表观遗传学分析工作流程方面领导了Covaris技术的努力。Khoja博士还领导了与美国国家癌症研究所的合作，成功开发了微生物组DNA提取Fibrobiologics，Inc.和声学，并完成了FDA EUA SARA-CoC-2桥研究设计，以批准新的样本采集和病毒核糖核酸（RNA）提取Fibrobiologics，Inc.和Covaris技术。Khoja博士还为Fibrobiologics，Inc.开发了一个制造合成无细胞DNA的专利工作流程，作为基于测序的液体活检临床肿瘤学分析的参考标准。在加入Covaris之前，霍亚博士于2022年3月至2009年3月在Genomic Solutions担任高级应用科学家，该公司是一家初创科学工具公司，后来被Harvard Apparatus收购。在那里，他领导了制药行业的高通量蛋白质结晶平台Fibrobiologics，Inc.的开发，用于药物开发，管理科学应用团队，在科学会议上展示公司资源，评估新技术，以获取收购和代工机会。从2000年1月到2003年3月，在Sequenom, Inc.的启动阶段，Khoja博士建立了高度多重聚合酶链反应的方法，即PCR，Fibrobiologics，Inc.开发了Sequenom的massEXTEND技术，用于单核苷酸多态性和遗传病的MALDI-TOF MS分析。Khoja博士领导了针对血色素沉着病、囊性纤维化和十种主要为犹太人的遗传病的基于MS的诊断检测，Fibrobiologics，Inc.和Sequenom的massEXTEND技术随后被转让给一家大型临床诊断公司。Khoja博士还曾于1998年11月至1999年9月在礼来公司工作，并于1995年10月至1998年10月在Chiron公司工作。在礼来工作期间，Khoja博士建立了一个高通量PCR和测序策略Fibrobiologics，Inc.，在1999年提供了各种测序策略和生物信息学工具，用于获得高覆盖基因组测序，最终完成了第一个完整的肺炎链球菌基因组序列。在后来被诺华收购的Chiron公司，Khoja博士帮助设计、开发和优化了FGFR、VEGF、PDGF和EPO受体的HTP结合分析，鉴定了新型g蛋白偶联的七种跨膜受体，鉴定了参与TNF信号通路的新型蛋白质，并开发了基于分支DNA的HTP筛选，用于配体诱导的癌基因定量。Khoja在南加州大学获得分子生物学学士学位，在波士顿大学获得分子生物学博士学位。
- Hamid Khoja has more than 25 years of experience leading scientific teams, developing cell based genomic, proteomic, and epigenetics assays, and tools, protocols, and technologies for e in drug discovery, and in development and clinical diagnostics. From March 2009 to Augt 2021, he served as the Principal Scientist at Covaris, LLC, or Corvaris, a privately held scientific tools company with emphasis in genomics, epigenetics, and proteomics. Prior to Covaris, from March 2002 to March 2009, Dr. Khoja was a Senior Applications Scientist at Genomic Solutions, a startup scientific tools company. Dr. Khoja also previoly worked at Eli Lilly and Company from November 1998 to September 1999 and Chiron Corporation from October 1995 to October 1998. Dr. Khoja received his Bachelor of Science in Molecular Biology from the University of Southern California and his Ph.D. in Molecular Biology from Boston University.
- Ruben A. Garcia
Ruben A. Garcia于2019年4月至2022年2月期间在制药公司AcelRx制药公司（n/k/a Talphera，Inc.）担任高级副总裁、总法律顾问和公司秘书。在加入AcelRX之前，Garcia先生于2016年11月至2019年4月在生物制药公司Ultragenyx Pharmaceutical Inc.担任高级公司法律顾问和助理秘书。在加入Ultragenyx之前，Garcia先生是Vinson & Elkins LLP和Jones Day的律师，在资本市场、证券发行、公司治理和并购领域执业。Garcia先生拥有乔治城大学政府和经济学学士学位和斯坦福大学法学院法学博士学位。
Ruben A. Garcia served as Senior Vice President, General Counsel and Corporate Secretary at AcelRx Pharmaceuticals, Inc. (n/k/a Talphera, Inc.), a pharmaceutical company, from April 2019 to February 2022. Prior to AcelRx, Mr. Garcia was Senior Corporate Counsel and Assistant Secretary at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, from November 2016 to April 2019. Prior to Ultragenyx, Mr. Garcia was an attorney at Vinson & Elkins LLP and Jones Day, where he practiced in the areas of capital markets, securities offerings, corporate governance and mergers and acquisitions. Mr. Garcia holds a B.A. in Government and Economics from Georgetown University and a J.D. from Stanford Law School.- Ruben A. Garcia于2019年4月至2022年2月期间在制药公司AcelRx制药公司（n/k/a Talphera，Inc.）担任高级副总裁、总法律顾问和公司秘书。在加入AcelRX之前，Garcia先生于2016年11月至2019年4月在生物制药公司Ultragenyx Pharmaceutical Inc.担任高级公司法律顾问和助理秘书。在加入Ultragenyx之前，Garcia先生是Vinson & Elkins LLP和Jones Day的律师，在资本市场、证券发行、公司治理和并购领域执业。Garcia先生拥有乔治城大学政府和经济学学士学位和斯坦福大学法学院法学博士学位。
- Ruben A. Garcia served as Senior Vice President, General Counsel and Corporate Secretary at AcelRx Pharmaceuticals, Inc. (n/k/a Talphera, Inc.), a pharmaceutical company, from April 2019 to February 2022. Prior to AcelRx, Mr. Garcia was Senior Corporate Counsel and Assistant Secretary at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, from November 2016 to April 2019. Prior to Ultragenyx, Mr. Garcia was an attorney at Vinson & Elkins LLP and Jones Day, where he practiced in the areas of capital markets, securities offerings, corporate governance and mergers and acquisitions. Mr. Garcia holds a B.A. in Government and Economics from Georgetown University and a J.D. from Stanford Law School.
- Jason D. Davis
Jason D. Davis，于2009年7月开始担任公司首席财务官、首席会计长兼公司秘书。2010年8月，他辞去首席财务官，并于2013年6月放弃公司秘书的职位。目前，他担任金融和会计副总裁。 Davis先生是一名注册会计师，曾在几家公司担任各种财务职务：2004年3月到2005年8月，担任Isolagen, Inc AMEX： ILE的财务主管助理；2005年8月到2006年6月，担任Texas Genco, LLC的SEC报告经理；2006年6月到2009年6月，担任Particle Drilling Technologies, Inc. （PDRT.PK）财务主管。Davis先生还曾于2009年1月至2009年6月期间担任Particle Drilling Technologies, Inc.的临时首席财务官。 另外，在获得University of Houston的会计和税务学士学位以后，他还曾于1997年到2003年在德勤会计师事务所担任会计师。
Jason D. Davis became our Chief Financial Officer, Principal Accounting Officer and Corporate Secretary in July 2009. In August 2010 Mr. Davis stepped down as the Chief Financial Officer and in June 2013 relinquished the position of Corporate Secretary. He currently serves as the Vice President of Finance and Treasurer. Mr. Davis is a licensed certified public accountant and has served in various financial positions for several companies including the Assistant Controller at Isolagen, Inc. AMEX: ILE from March 2004 to August 2005 the Manager of SEC Reporting at Texas Genco, LLC from August 2005 to June 2006 and the Controller at Particle Drilling Technologies, Inc.(PDRT.PK) from June 2006 to June 2009. Mr. Davis also served as the interim Chief Financial Officer for Particle Drilling Technologies, Inc. from January 2009 to June 2009. Mr. Davis was an accountant with Deloitte & Touche LLP after obtaining his BBA in Accountancy and Taxation from the University of Houston in 1997 until 2003.- Jason D. Davis，于2009年7月开始担任公司首席财务官、首席会计长兼公司秘书。2010年8月，他辞去首席财务官，并于2013年6月放弃公司秘书的职位。目前，他担任金融和会计副总裁。 Davis先生是一名注册会计师，曾在几家公司担任各种财务职务：2004年3月到2005年8月，担任Isolagen, Inc AMEX： ILE的财务主管助理；2005年8月到2006年6月，担任Texas Genco, LLC的SEC报告经理；2006年6月到2009年6月，担任Particle Drilling Technologies, Inc. （PDRT.PK）财务主管。Davis先生还曾于2009年1月至2009年6月期间担任Particle Drilling Technologies, Inc.的临时首席财务官。 另外，在获得University of Houston的会计和税务学士学位以后，他还曾于1997年到2003年在德勤会计师事务所担任会计师。
- Jason D. Davis became our Chief Financial Officer, Principal Accounting Officer and Corporate Secretary in July 2009. In August 2010 Mr. Davis stepped down as the Chief Financial Officer and in June 2013 relinquished the position of Corporate Secretary. He currently serves as the Vice President of Finance and Treasurer. Mr. Davis is a licensed certified public accountant and has served in various financial positions for several companies including the Assistant Controller at Isolagen, Inc. AMEX: ILE from March 2004 to August 2005 the Manager of SEC Reporting at Texas Genco, LLC from August 2005 to June 2006 and the Controller at Particle Drilling Technologies, Inc.(PDRT.PK) from June 2006 to June 2009. Mr. Davis also served as the interim Chief Financial Officer for Particle Drilling Technologies, Inc. from January 2009 to June 2009. Mr. Davis was an accountant with Deloitte & Touche LLP after obtaining his BBA in Accountancy and Taxation from the University of Houston in 1997 until 2003.